Pharmacokinetics and Biotransformation of Mirtazapine in Human Volunteers

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Clinical drug investigation

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2165/00044011-199815010-00006PMID 18370465
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The clinical relevance of preclinical data: mirtazapine, a model compound.

  1997cited by this paper
• In Vitro and In Vivo Studies on the Disposition of Mirtazapine in Humans

  1997cited by this paper
• (+)-Mirtazapine and (+)-desmethylmirtazapine levels in rat brain in relation to in vivo blockade of α2 receptors

  1996cited by this paper
• Mirtazapine

  1996cited by this paper
• Pharmacokinetic dose‐proportionality study at steady state of mirtazapine from Remeron® tablets

  1995cited by this paper
• The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission

  1995cited by this paper
• The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission.

  1995cited by this paper
• Bioavailability of mirtazapine from Remeron® tablets after single and multiple oral dosing

  1995cited by this paper
• Metabolism of three pharmacologically active drugs in isolated human and rat hepatocytes: analysis of interspecies variability and comparison with metabolism in vivo.

  1994cited by this paper
• Analytical methods validation

  1993cited by this paper
• The synthesis of org 3770 labelled with 3H, 13C AND 14C

  1989cited by this paper
• Synthesis and applications of isotopically labelled compounds

  1988cited by this paper
• A mass spectrometric approach to the identification of conjugated drug metabolites.

  1987cited by this paper
• Synthesis of Glucuronides Derived from the Antidepressant Drugs Mianserin and Org3770.

  1986cited by this paper

• Prediction and Validation of Phase II Glucuronide Conjugates in Urine Using Combined Non-Targeted and Targeted LC–HRMS/MS Workflows and Their Validation for over 200 Drugs

  2026cites this paper
• Mirtazapine revisited: new therapeutic perspectives and formulation advances

  2025influential citation
• Optimizing therapeutic drug monitoring of mirtazapine — applying therapeutic reference range, concentration–dose ratio/dose-related concentration, and metabolic ratio in a naturalistic setting

  2025cites this paper
• Exploring Domestic Discharge Patterns in Wastewater through LC-HRMS Screening and Temporal Clustering

  2025cites this paper
• Novel therapies for nausea and vomiting in advanced illness and supportive cancer care

  2024cites this paper
• Environmentally relevant concentrations of antidepressant mirtazapine impair the neurodevelopment of zebrafish (Danio rerio).

  2023cites this paper
• Pharmacological update of mirtazapine: a narrative literature review

  2023cites this paper
• Catchment area, fate, and environmental risks investigation of micropollutants in Danish wastewater

  2023cites this paper
• Citalopram and Cannabidiol

  2021influential citation
• Effects of the antidepressant mirtazapine on the swimming behaviour and gene expression rate of Danio rerio embryos - Is the sedating effect seen in humans also evident for fish?

  2021cites this paper
• New-generation, non-SSRI antidepressants: Drug-drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others.

  2020cites this paper
• Mirtazapine and Depressions

  2020cites this paper
• Is There Enough Evidence to Classify Cycloalkyl Amine Substituents as Structural Alerts?

  2020cites this paper
• 8-Hydroxylation and Glucuronidation of Mirtazapine in Japanese Psychiatric Patients: Significance of the Glucuronidation Pathway of 8-Hydroxy-Mirtazapine

  2018influential citation
• Highly selective N-glucuronidation of four piperazine-containing drugs by UDP-glucuronosyltransferase 2B10

  2018cites this paper
• Mirtazapine.

  2018cites this paper
• Liabilities Associated with the Formation of "Hard" Electrophiles in Reactive Metabolite Trapping Screens.

  2017cites this paper
• The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset

  2017cites this paper
• Mirtazapine fatal poisoning.

  2017cites this paper
• Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model

  2017cites this paper
• Formulation studies for mirtazapine orally disintegrating tablets

  2016cites this paper
• Distribution pattern of mirtazapine and normirtazapine in blood and CSF

  2015cites this paper
• Studies on drug metabolism by fungi colonizing decomposing human cadavers. Part II: biotransformation of five model drugs by fungi isolated from post-mortem material.

  2015cites this paper
• Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients.

  2015cites this paper
• Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications

  2015cites this paper
• PHARMACOLOGICAL STIMULATION Rational choices in the inappetent cat

  2015cites this paper
• Factors Affecting Steady-state Plasma Concentrations of Enantiomeric Mirtazapine and its Desmethylated Metabolites in Japanese Psychiatric Patients

  2015cites this paper
• Pharmacological appetite stimulation

  2014cites this paper
• SHORT COMMUNICATION: PHARMACOKINETICS OF MIRTAZAPINE AND ITS MAIN METABOLITES AFTER SINGLE INTRAVENOUS AND ORAL ADMINISTRATIONS IN RATS AT TWO DOSE RATES

  2014cites this paper
• Pharmacokinetics of mirtazapine and its main metabolites after single intravenous and oral administrations in rats at two dose rates

  2014cites this paper
• Pharmakogenetische Untersuchungen psychiatrischer Patienten: Bestimmung ausgewählter genetischer Varianten in pharmakokinetischen und pharmakodynamischen Strukturen und deren Bedeutung für die Psychopharmakotherapie

  2014cites this paper
• Drug Response Heterogeneity and the Genetic Variability of Cytochrome P450–Metabolizing Enzymes

  2014cites this paper
• Pharmacotherapy for Mood Disorders in Pregnancy: A Review of Pharmacokinetic Changes and Clinical Recommendations for Therapeutic Drug Monitoring

  2014cites this paper
• Enantioselective Separation of Mirtazapine and Its Metabolites by Capillary Electrophoresis with Acetonitrile Field-Amplified Sample Stacking and Its Application

  2014cites this paper
• A Rapid and Sensitive HPLC-Fluorescence Method for Determination of Mirtazapine and Its two Major Metabolites in Human Plasma

  2014cites this paper
• Pharmacokinetics of Mirtazapine and Its Main Metabolites after Single Oral Administration in Fasting/Fed Horses

  2013cites this paper
• A review of therapeutic uses of mirtazapine in psychiatric and medical conditions.

  2013cites this paper
• Multicenter Study on the Clinical Effectiveness, Pharmacokinetics, and Pharmacogenetics of Mirtazapine in Depression

  2012cites this paper
• Pharmacokinetics of mirtazapine and its main metabolites in Beagle dogs: a pilot study.

  2012cites this paper
• Neurobiology of depression and novel antidepressant drug targets.

  2012cites this paper
• A semi-automated method for the integrated evaluation of half-life and metabolic soft spots of discovery compounds.

  2012cites this paper
• Mirtazapine in Veterinary Medicine a Pharmacological Rationale for its Application in Chronic Pain

  2012cites this paper
• Monographs on drugs which are frequently analyzed in therapeutic drug monitoring/Arzneimittel-Monographien für Medikamente, die regelmäßig im Rahmen des Therapeutic Drug Monitorings analysiert werden

  2012cites this paper
• A fast, sensitive and simple method for mirtazapine quantification in human plasma by HPLC-ESI-MS/MS. Application to a comparative bioavailability study.

  2012cites this paper
• Review of the use of mirtazapine in the treatment of depression

  2011cites this paper
• Development and Validation of an LC-MS/MS Method for Quantitative Analysis of Mirtazapine in Human Plasma

  2011cites this paper
• TOOLS IN PHARMACOVIGILANCE IN PSYCHIATRY: THERAPEUTIC DRUG MONITORING, PHARMACOGENETIC TESTS AND DRUG-DRUG INTERACTIONS DATABASES

  2011cites this paper
• Methamphetamine withdrawal: clinical profile, assessment and treatment

  2010cites this paper
• Getting the balance right: Established and emerging therapies for major depressive disorders

  2010cites this paper
• Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects

  2010cites this paper
• Embryotoxicity of mirtazapine: a study using Chick Embryotoxicity Screening Test.

  2010cites this paper
• Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development.

  2009cites this paper
• Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites.

  2009cites this paper
• Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

  2009cites this paper
• Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment.

  2009cites this paper
• Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development.

  2009cites this paper
• Chiral determination of antidepressant drugs and their metabolites in biological samples.

  2009cites this paper
• Steady-State Concentrations of Mirtazapine, N-Desmethylmirtazapine, 8-Hydroxymirtazapine and their Enantiomers in Relation to Cytochrome P450 2D6 Genotype, Age and Smoking Behaviour

  2009cites this paper
• Development and validation of a reversed-phase HPLC method for separation and simultaneous determination of process-related substances of mirtazapine in bulk drugs and formulations.

  2009cites this paper
• Mirtazapine

  2009cites this paper
• Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

  2009cites this paper
• Mirtazapine Review of its Use in Major Depression and Other

  2009cites this paper
• Monographs on drugs which are frequently analyzed in therapeutic drug monitoring/Arzneimittel-Monographien für Medikamente, die regelmäßig im Rahmen des Therapeutic Drug Monitorings analysiert werden

  2009cites this paper
• Monographs on drugs which are frequently analyzed in therapeutic drug monitoring / Arzneimittel-Monographien für Medikamente, die regelmäßig im Rahmen des Therapeutic Drug Monitorings analysiert werden

  2009cites this paper
• Polymorphism of human cytochrome P450 enzymes and its clinical impact

  2009cites this paper
• Capillary electrophoretic chiral determination of mirtazapine and its main metabolites in human urine after enzymatic hydrolysis

  2008cites this paper
• Enantioselective analysis of mirtazapine and its two major metabolites in human plasma by liquid chromatography-mass spectrometry after three-phase liquid-phase microextraction.

  2008cites this paper
• Pharmacokinetics of Mirtazapine: Enantioselective Effects of the CYP2D6 Ultra Rapid Metabolizer Genotype and Correlation with Adverse Effects

  2007influential citation
• Mirtazapine Enantiomers in Blood and Cerebrospinal Fluid

  2007cites this paper
• Enantioselective separation of the novel antidepressant mirtazapine and its main metabolites by CEC

  2007cites this paper
• What is the Objective of the Mass Balance Study? A Retrospective Analysis of Data in Animal and Human Excretion Studies Employing Radiolabeled Drugs

  2007influential citation
• Drug monographs on drugs which are frequently analysed in the context of Therapeutic Drug Monitoring / Arzneimittel-Monographien für Medikamente, die regelmäßig im Rahmen des Therapeutic Drug Monitorings analysiert werden

  2006cites this paper
• A review of the pharmacological and clinical profile of mirtazapine.

  2006cites this paper
• Advances in the enantioseparation of second‐generation antidepressant drugs by electrodriven methods

  2006cites this paper
• Therapeutic Drug Monitoring of Mirtazapine, Desmethylmirtazapine, 8-Hydroxymirtazapine, and Mirtazapine-N-oxide by Enantioselective HPLC With Fluorescence Detection

  2006cites this paper
• Tissue distribution of mirtazapine and desmethylmirtazapine in a case of mirtazapine poisoning.

  2006cites this paper
• Determination of the antidepressant mirtazapine and its two main metabolites in human plasma by liquid chromatography with fluorescence detection

  2006cites this paper
• Chiral liquid chromatographic determination of mirtazapine in human plasma using two-phase liquid-phase microextraction for sample preparation

  2005cites this paper
• Development and validation of HPLC methods for enantioseparation of mirtazapine enantiomers at analytical and semipreparative scale using polysaccharide chiral stationary phases

  2005cites this paper
• Inter- and Intraindividual Pharmacokinetic Variations of Mirtazapine and Its N-Demethyl Metabolite in Patients Treated for Major Depressive Disorder: A 6-Month Therapeutic Drug Monitoring Study

  2005cites this paper
• Enantiomeric separation of mirtazapine and its metabolites by nano-liquid chromatography with UV-absorption and mass spectrometric detection.

  2005cites this paper
• Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance

  2005cites this paper
• Therapeutic Drug Monitoring of Mirtazapine and Its Metabolite Desmethylmirtazapine by HPLC with Fluorescence Detection

  2004cites this paper
• New Formulations of Existing Antidepressants

  2004cites this paper
• A validated liquid chromatographic tandem mass spectrometric method for the determination of mirtazapine and demethylmirtazapine in human plasma: application to a pharmacokinetic study

  2004cites this paper
• Enantioselective determination of the novel antidepressant mirtazapine and its active demethylated metabolite in human plasma by means of capillary electrophoresis.

  2004cites this paper
• New method for the chiral evaluation of mirtazapine in human plasma by liquid chromatography.

  2004cites this paper
• Population pharmacokinetic analysis of mirtazapine

  2004cites this paper
• Chirality in the New Generation of Antidepressants: Stereoselective Analysis of the Enantiomers of Mirtazapine, N-Demethylmirtazapine, and 8-Hydroxymirtazapine by LC-MS

  2004influential citation
• Escitalopram versus citalopram: the surprising role of the R-enantiomer

  2004cites this paper
• Mirtazapine in combination with amitriptyline: a drug–drug interaction study in healthy subjects

  2003cites this paper
• Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy.

  2002cites this paper
• [11C]Mirtazapine for PET neuroimaging: radiosynthesis and initial evaluation in the living porcine brain.

  2002cites this paper
• Biotransformation of mirtazapine by Cunninghamella elegans.

  2002influential citation
• Clinical Pharmacokinetics of Mirtazapine

  2000cites this paper
• Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4.

  2000influential citation
• Determination of mirtazapine in tablets by UV spectrophotometric and derivative spectrophotometric methods.

  2000cites this paper
• Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: a comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism.

  2000influential citation
• High-performance liquid chromatographic assay with fluorescence detection for the routine monitoring of the antidepressant mirtazapine and its demethyl metabolite in human plasma.

  1999cites this paper
• Mirtazapine

  1999cites this paper